Ind-Swift Laboratories share news, announcements and annual reports
NSE: INDSWFTLABBSE: 532305Pharmaceuticals & BiotechnologySmall Cap
Ind-Swift Laboratories Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 1997 on NSE, Mar 2000 on BSE
Last close ₹368.20down ₹41.60 (10.15%)BSE ₹367.40
Share price at the NSE close on 30 Oct 2026. Previous close ₹409.80.
30 Oct: open ₹417.90, high ₹426.60, low ₹352.35
52-week range of traded prices to 30 Oct 2026
₹87.15Low, 31 Dec 2025₹426.60High, 30 Oct 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹3,202 Cr1,404th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 38.32
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹12 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 33.57
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.17
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 6.0%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹12 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 6.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 4.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 36,07,65931.1% delivered
Ind-Swift Laboratories share news and announcements
911 announcements, routine notices left out, newest first. Page 13 of 19.
Sep 2018
Aug 2018
14 Aug · Results
3 Aug · Board meeting
1 Aug · Updates
Jul 2018
25 Jul · Board meeting
21 Jul · Board meeting
8 Jul · Legal
Exchange has sought clarification from Ind-Swift Laboratories Limited with respect to announcement dated 05-Jul-2018, regarding " Ind-Swift Laboratories Limited has informed the Exchange regarding 'Intimation of Minor Fire at R&D Centre, Mohali, Punjab' pursuant to regulation 30 of the SEBI (LODR) Regulations, 2015'.". On basis of above the Company is required to clarify following: 1. Whether loss/damage covered by insurance or not including amount; 2. Expected quantum of loss/damage caused; The response of the Company is awaited.4 Jul · Updates
Jun 2018
22 Jun · Updates
14 Jun · Management
13 Jun · Board meeting
4 Jun · Legal
Exchange has sought clarification from Ind-Swift Laboratories Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone Reconciliation of profit and loss not submitted -2. Standalone Reconciliation of Equity not submitted -3. Consolidated Reconciliation of profit and loss not submitted -4. Consolidated Reconciliation of Equity not submitted The response of the Company is awaited.4 Jun · Board meeting
May 2018
30 May · Results
30 May · Board meeting
7 May · Board meeting
3 May · Legal
Exchange has sought clarification from Ind-Swift Laboratories Limited with respect to announcement dated 02-May-2018, regarding " Ind-Swift Laboratories Limited has informed the Exchange regarding Board meeting held on May 02, 2018.". On basis of above the Company is required to clarify following: 1. Details of redemption of preference shares indicating the manner of redemption (whether out of profits or out of fresh issue) and debentures. 2. Details of any letter or comments regarding payment/non-payment of interest, principal on due dates, or any other matter concerning the security and /or the assets along with its comments thereon, if any; 3. Delay in payment of interest / principal amount for a period of more than three months from the due date or default in payment of interest / principal; 4. Special right/interest/privileges attached to the instrument and changes thereof; 5. Charge/security, if any, created over the assets; 6. Coupon/interest offered, schedule of payment of coupon/interest and principal; 7. Tenure of the instrument - date of allotment and date of maturity; 8. Whether proposed to be listed? If yes, name of the stock exchange(s); The response of the Company is awaited.2 May · Board meeting
Apr 2018
27 Apr · Board meeting
Mar 2018
6 Mar · Updates
Feb 2018
13 Feb · Board meeting
13 Feb · Results
Jan 2018
Dec 2017